Mostrando 10 resultados de: 37
Filtros aplicados
Publisher
Pharmacogenomics Journal(9)
Pharmacogenomics(7)
Current Drug Targets(2)
Drug Metabolism and Drug Interactions(2)
European Journal of Clinical Pharmacology(2)
Área temáticas
Farmacología y terapéutica(22)
Bioquímica(7)
Fisiología humana(5)
Medicina y salud(5)
Psicología diferencial y del desarrollo(3)
Área de conocimiento
Farmacología(21)
Genética(13)
Psicopatología(10)
Trastorno depresivo mayor(3)
Salud mental(2)
Origen
scopus(37)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAssociation between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
ArticleAbstract: Background: An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has bPalabras claves:A-1438G polymorphism, Risperidone, Schizophrenia, Seretonin 2A receptor, T102C polymorphismAutores:Adrián LLerena, Cáceres M.C., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAssociation of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDetermination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
ArticleAbstract: A rapid high-performance liquid chromatographic method is described for the simultaneous determinatiPalabras claves:Fluoxetine, NorfluoxetineAutores:Adrián LLerena, Berecz R., Cáceres M.C., De la Rubia A., Dorado P., González A.P., Jesus Norberto M.Fuentes:scopusCYP2C9 gene and susceptibility to major depressive disorder
ArticleAbstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disPalabras claves:CYP2C9 gene, Depression, SchizophreniaAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 polymorphism and mental and personality disorders in suicide attempters
ArticleAbstract: Prior studies on the association between the CYP2D6 polymorphism and suicide did not explore whetherPalabras claves:Autores:Adrián LLerena, Baca-García E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Saiz-Ruiz J., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopus